Hamdan Bin Mohammed College of Dental Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
Department of Dentistry, European University Cyprus, Nicosia, Cyprus.
PLoS One. 2023 May 4;18(5):e0285309. doi: 10.1371/journal.pone.0285309. eCollection 2023.
The aim of this study is to systematically investigate the available evidence from human studies regarding the association of asthma and/or allergy with EARR.
Unrestricted searches in 6 databases and manual searching were performed up to May 2022. We looked for data on EARR after orthodontic treatment in patients with/without asthma or allergy. Relevant data were extracted, and the risk of bias was assessed. An exploratory synthesis was carried out using the random effects model, and the overall quality of the evidence was assessed with the Grades of Recommendation, Assessment, Development, and Evaluation.
From the initially retrieved records, nine studies met the inclusion criteria (three cohort and six case-control). Overall, increased EARR was observed in the individuals with allergies in their medical history (Standardised Mean Difference [SMD]: 0.42, 95% Confidence Interval [CI]: 0.19 to 0.64). No difference in EARR development was observed among individuals with or without a medical history of asthma (SMD: 0.20, 95% CI: -0.06 to 0.46). The quality of available evidence, excluding studies at high risk, was rated as moderate for the exposure to allergy, and low for the exposure to asthma.
Increased EARR was noted in individuals with allergies compared to the control group, while no difference was observed for individuals with asthma. Until more data become available, good practice would suggest that it is important to identify patients with asthma or allergy and consider the possible implications.
本研究旨在系统调查有关哮喘和/或过敏与 EARR 相关性的人类研究证据。
截至 2022 年 5 月,我们在 6 个数据库中进行了无限制检索并进行了手工检索。我们寻找了正畸治疗后有/无哮喘或过敏患者的 EARR 数据。提取相关数据,并评估偏倚风险。使用随机效应模型进行探索性综合分析,并使用推荐评估、发展和评估(Grades of Recommendation, Assessment, Development, and Evaluation,GRADE)评估证据的总体质量。
从最初检索到的记录中,有 9 项研究符合纳入标准(3 项队列研究和 6 项病例对照研究)。总体而言,有过敏病史的个体 EARR 增加(标准化均数差 [SMD]:0.42,95%置信区间 [CI]:0.19 至 0.64)。有或无哮喘病史的个体 EARR 发展无差异(SMD:0.20,95%CI:-0.06 至 0.46)。排除高风险研究后,过敏暴露的证据质量被评为中等,哮喘暴露的证据质量被评为低等。
与对照组相比,过敏个体的 EARR 增加,而哮喘个体则没有差异。在更多数据可用之前,良好的做法是建议识别有哮喘或过敏的患者,并考虑可能的影响。